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When  the  third  component  of complement,  C3,  is  proteolytically activated,  the 
resulting fragment, C3b, binds covalently to receptive surfaces (1). In the presence of 
serum factors/~IH (H) 1 and I, C3b is rapidly cleaved to yield an altered form, C3b', 
which is relatively stable  in serum  (2).  Human  monocytes recognize both  C3b  and 
C3b', and several lines of evidence indicate that monocytes bear separate receptors for 
each of these two forms of C3 (3-5). Both C3b and C3b' receptors efficiently mediate 
the  attachment  of erythrocytes  coated  with  their  respective  ligands,  but  neither 
receptor is an efficient mediator of phagocytosis (6). 
Resident  peritoneal  macrophages  of the  mouse also bind  C3-coated erythrocytes 
without  ingesting  them  (7).  However,  these  cells  become capable  of ingesting  C3- 
coated erythrocytes after treatment  with a  soluble factor secreted by T  lymphocytes 
(8-10).  These  findings  prompted  us  to  search  for  compounds  that  stimulate  the 
phagocytic  capacity  of the  C3b  and  C3b'  receptors  on  human  monocytes and  to 
examine the functional relationships between the two C3 receptors. 
To  obtain  suspensions  of cultured  monocytes  for  use  in  these  experiments,  we 
adapted the Percoll purification method of Gmelig-Meyling and Waldmann (11) and 
the  Teflon  culture  method  of van  der  Meer  et  al.  (12).  Using  these  methods,  we 
routinely recover 75-85% of all monocytes present in a blood sample and can observe 
differentiation  of this  population  without  selective cell  loss during culture.  We find 
that treatment of these monocytes with tumor-promoting phorbol esters renders their 
C3b  and  C3b'  receptors  capable  of efficiently  and  independently  promoting  the 
phagocytosis  of erythrocytes  coated  with  the  corresponding  ligands  and  that  the 
capacity of the monocytes to respond to phorbol esters is developmentally regulated. 
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1  Abbreviations  used in this paper." AI, attachment index; DNP, rabbit anti-DNP-IgG; DFP, diisopropylfluo- 
rophosphate; DGVB  +÷, 2.5 mM veronal buffer, pH 7.5, 75 mM NaCI, 2.5% dextrose, 0.05% gelatin, 0.15 
mM CaCI2, 0.5 mM MgC12; DNP, dinitrobenzene; E, sheep erythrocytes; EIgM, E coated with rabbit 
anti-E IgM; EIgG, E coated with rabbit  anti-E IgG; EC3b, EIgM coated with complement components 
C1, C4, C2, and C3; EC3b', EC3b treated with I; EC3d, EC3b', treated with trypsin; H, fllH; HSA, 
human serum albumin; I, C3b-inactivator; NHS, normal human serum; NSE, nonspecific esterase; PBS, 
phosphate-buffered saline with Ca and Mg ions; PBSG, PBS containing 3 mM glucose; PD, PBS deficient 
in  Ca and Mg ions; PDD,  phorbol-12,13-didecanoate; 4-a-PDD,  4-a-phorbol-12,13-didecanoate; 4-a- 
PHR, 4-a-phorbol; PI, phagocytic index; PLL, poly-L-lysine;  PMA, phorbol-12-myristate-13-acetate; PTA, 
phorbol-12,13-20-triacetate; SBTI, soybean trypsin inhibitor; SDS, sodium dodecyl sulfate. 
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Materials and Methods 
Reagents.  Purified human C3 was a gift from Drs. S. K. Law and R. P. Levine, Washington 
University School of Medicine, St. Louis, MO. Cordis Laboratories Inc. (Miami, FL) supplied 
C 1  gp, C2  gp, C4  gp, I, cobra venom factor, and anti-sheep erythrocyte IgG and IgM. Fab fragments 
of mouse  monoclonal anti-C3 IgG  (Bethesda  Research  Laboratories,  Rockville, MD)  were 
made by the  method of Porter  (13) and were  purified by affinity chromatography on C3- 
zymosan (14). Soybean trypsin inhibitor (SBTI), trypsin, and papain were products of Worth- 
ington Biochemicals  (Freehold,  N  J);  phorbol-12,I  3-didecanoate  (PDD),  4-a-phorbol-  12,13- 
didecanoate (4-a-PDD), phorbol- 12,13,20-triacetate (PTA), and 4-a-phorbol (4-a-PHR) were 
supplied by Vega-Fox Biochemical Division (Tucson, AZ). Percoll, Sepharose 4B, and Ficoll- 
Paque were products of Pharmacia Fine Chemicals (Div.  Pharmacia Inc., Piscataway, N  J). 
Sigma Chemical Co.  (St. Louis, MO) supplied 3,3'-diaminobenzidine  (DAB),  a-naphthylbu- 
tyrate, pararosanaline, methyl green, colchicine, podophyllotoxin, diisopropyl fluorophosphate 
(DFP), poly-L-lysine (PLL), cycloheximide, Triton X-100, phenolphthalein glucuronic acid, 
fl-glucuronidase, phorbol-12-myristate-13-acetate (PMA),  and  conconavalin A.  K76COOH 
was a generous gift of Dr. K. Inoue, Osaka University Medical School, Osaka, Japan. Normal 
human serum was obtained using type A, Rh  + blood from healthy volunteers as described (15). 
Radioiodination and Gel Analysis.  C3, rabbit anti-sheep erythrocyte IgG, and monoclonal anti- 
C3 Fab fragments were iodinated by the iodogen method as described (16), yielding proteins 
with specific activities of 2 X  105-2 ×  l0  s cpm//~g.  No alterations in the hemolytic activity of 
C3 was measurable after iodination. The polypeptide structure of erythrocyte-bound iodinated 
C3 was determined by sodium dodecyl sulfate (SDS)  polyacrylamide gel electrophoresis (17) 
after base-catalyzed scission of the ester linkage between C3 and the erythrocyte surface (14). 
Enzyme and Protein Assays.  Monocyte pellets were lysed with 0.5% Triton X-100 and the 
activity of fl-glucuronidase in the lysate was determined by the hydrolysis of phenolphthalein- 
fl-glucuronide as described (18). Units of enzyme activity were calculated by comparison with 
a  standard fl-glucuronidase preparation (Sigma Chemical Co.)  assayed  in parallel. Protein 
concentration was determined by the method of Lowry et al. (19). 
Cytochemistry.  1-2 ×  10  s cells were deposited on glass slides using a Shandon cytocentrifuge 
(Shandon Southern Products Ltd., Astmoor, U. K.) set to 500 rpm. After air drying, the slides 
were  stained to reveal nonspecific esterase  activity (20),  peroxidase activity (21),  or nuclear 
morphology (Diff-Quik; Harleco, Gibbstown, N  J). 
Ligand-bearing  Erythrocytes.  Sheep  erythrocytes  (E)  (Laboratory Animal Research  Center, 
The Rockefeller University) were coated with either rabbit anti-E IgG or IgM according to 
Nelson et al.  (22), yielding EIgG or EIgM, respectively. The IgM was adsorbed with Staphylo- 
coccus aureus (Bethesda  Research  Laboratories)  to  remove  residual IgG and  was  used  at  a 
subagglutinating  concentration that corresponded to ~200 IgM/E by hemolytic analysis (23). 
In some experiments, radioiodinated anti-E IgG was  used to determine the number of IgG 
molecules per E. Binding of 125I-IgG  to E was a linear function of the quantity of IgG used, and 
aggregation of E began to occur at concentrations exceeding 100,000 IgG/E. Unless otherwise 
stated, EIgG were prepared so as to bear ~40,000 IgG/E. EIgG were used up to 2 d after their 
preparation. 
C3-bearing E were produced using a modification of the method of Law et al. (2). Briefly, 
10  s EIgM in 1 ml veronal buffer with dextrose and gelatin (DGVB  ++) were treated sequentially 
with 40 U  C1  gp (0°C, 40 min), 100 U  C4  ~  (30°C, 40 rain), and  100 U  C2  gp (30°C,  10 min), 
with a wash in DGVB  ++ between steps. The amounts of complement components C 1, C4, and 
C2 were adjusted to yield 200 hemolytic sites per E. The resultant EIgMC 142 were immediately 
washed in DGVB  ÷+, resuspended in 0.5 ml DGVB  ++ containing 75/~g  C3,  incubated for 30 
min at 37°C, and washed twice in DGVB  ++. The resulting cells (EC3b) were strongly immune 
adherence positive (2)  and were agglutinahle by anti-C3c and anti-C3d (Accurate Chemical 
& Scientific Corp., Westbury, NY). Furthermore, all cell-bound 125I-C3ba polypeptide exhibited 
an Mr of 130,000 on SDS polyacrylamide gels. 
The procedure described above resulted in ~100,000  C3  molecules deposited  per  E.  To 
obtain E bearing different amounts of C3, the quantity of C3 added to the EIgMC142 was 
varied. The amount of C3 attached to the E was quantitated by the binding of '25I-Fab-anti- 
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FIG.  1.  SDS electrophoresis  of erythrocyte-bound C3.  Erythrocytes were coated with 125I-C3 and 
prepared for electrophoretic analysis of their bound C3 as described in Materials and Methods. An 
autoradiogram of the resulting gel is shown.  Lane A,1~5I-C3; lane B, EC3b; lane C, EC3b'; lane D, 
EC3d. 
A  portion of the EC3b preparation  was treated with factor I  to convert cell-bound C3b to 
C3b':  0.5  ×  l0  s  EC3b  in 0.5  ml  DGVB  ++  were incubated  with  75  U  of I, which  had  been 
treated  with  DFP  as  described  (2).  After 2  h  at  37°C,  the  conversion  of C3b  to  C3b'  was 
complete as assessed by SDS gel analysis of iodinated C3; all a~SI-C3a polypeptide appeared as 
a 60,000-Mr fragment. However, a small amount of C3b remained on the surface as assessed by 
a  weakly positive immune adherence  reaction.  Therefore, the factor I  treatment  was  supple- 
mented  by a  5-min  incubation  with  1% human  serum  that  had  been exhaustively adsorbed 
with  sheep  E  and  decomplemented  with  cobra  venom  factor  (20  U/ml,  37°C,  2  h).  This 
treatment  abolished  remaining  immune  adherence  activity  and  did  not  alter  the  SDS  gel 
pattern of radioiodinated, cell-bound C3b'. EC3b' could be agglutinated by both anti-C3c and 
anti-C3d serum. EC3b' were treated with trypsin to convert cell-bound C3b' to C3d: 0.5 ×  l0  s 
EC3b' in 0.5 ml DGVB  ++ were incubated with 5 #g trypsin for 5 min at 37°C. The trypsin was 
inhibited with a  10-fold excess of SBTI, and the cells were washed three times. The resultant 
EC3d  were  immune  adherence  negative,  could  not  be  agglutinated  by  anti-C3c,  could  be 
agglutinated  with  anti-C3d,  and  bore  a  reduced  quantity  of a25I-C3,  which  appeared  as  a 
30,000-Mr  species on  SDS  gels.  Fig.  1 shows  SDS  gel analysis  of a2nI-C3  eluted  from  EC3b, 
EC3b', and EC3d prepared  as described above. EC3b, EC3b', and EC3d were stored on ice in 
DGVB  ++ containing penicillin and streptomycin for up to 10 d  with no loss of rosette-forming 
capacity and <10% loss of ~25I-C3. 
Ligand-bearing Culture Surfaces.  IgG-bearing surfaces were prepared  by sequentially treating 
tissue culture plastic with PLL, dinitrophenol  (DNP),  and  anti-DNP exactly as described by 
Michl et al. (24).  Complement was deposited on IgG-bearing surfaces using purified C 1  go, C4  go, 
C2  g°, and C3 as described for the production of EC3b and EC3b'. The resulting surfaces bore 
both anti-DNP-IgG and either C3b or C3b'. 
Phagocytosis and Attachment Assays.  The ability of mononuclear phagocytes to bind and ingest 
ligand-coated E was measured using a microassay performed with Terasaki plates (3040; Falcon 
Labware, Oxnard, CA). Terasaki plates were pretreated with 5 mg/ml human serum albumin 
(HSA) for 30 min at room temperature and washed.  (Phagocytic indices were depressed if this 
step was omitted.)  Phagocytes were brought  to a  concentration  of 5  ×  105/ml  in  phosphate- 
buffered saline (PBS) containing 3 mM glucose (PBSG), and 5 #1 of this suspension was added 
to each Terasaki  well. After 45 rain at  37°C,  the plates were washed by dipping in PBS, and 1152  ACTIVATION OF C3  RECEPTORS  ON  CULTURED HUMAN  MONOCYTES 
the level of fluid in each well was reduced to <2 #l by aspiration. 5/~1 of ligand-bearing E  (10s/ 
ml in DGVB ++) was added  to each well, and the plates were again incubated  at 37°C for 45 
min.  Nonattached  E  were removed from wells with a  controlled stream  of buffer applied by 
passing PBS deficient in Mg and Ca ions (PD)  through a  10-/~1 capillary micropipette (Yankee 
Micropet; Clay Adams, Parsippany,  NJ)  using a  pressure  head of 50 cm of H20.  Some wells 
were dipped in distilled water five times for 1 s each to lyse uningested E, and then all samples 
were  fixed  with  2.5%  glutaraldehyde  in  PD.  The  number  of attached  or  ingested  E  was 
determined by phase-contrast  microscopy using an inverted microscope (Carl Zeiss, Inc., New 
York)  with  a  40×  water-immersion  objective.  The  percent  of phagocytes  that  attached  or 
ingested E multiplied by the average number of E per phagocyte is expressed as attachment  or 
phagocytic index, respectively. At least  100 cells in duplicate wells were counted for each data 
point. 
E-bearing Culture Surfaces.  E were attached as a monolayer to Terasaki wells by the following 
protocol.  Surfaces were treated with 0.1  mg/ml PLL in PD for 30 min at  room temperature. 
After a  thorough wash in PD, each well received 106 E  in PD and  plates were centrifuged at 
400 g for 5 min. Excess E  were removed by vigorous dipping in PD, and remaining PLL was 
neutralized by incubation with  1 mg/ml HSA for 30 rain. The adherent  E  were converted to 
ghosts (G) by incubating them five times for 1 s in 5 mM sodium phosphate,  pH 8. 
Preparation of Percoll Gradients.  Preformed Percoll gradients were constructed by a  modifica- 
tion of the procedures published  by several laboratories  (11,  25-27).  Percoll was first brought 
to isotonicity by the addition of 0.1  vol of 10X-concentrated  PD.  1 ml normal  human  serum 
(NHS),  14.7  ml  PBS,  and  22  ml  isotonic  Percoll  were  mixed  in  each  of four sterile  50-ml 
polycarbonate  centrifuge tubes  (Dupont  Instruments,  Newton, CT), and  the tubes were then 
centrifuged for 25 rain at  18,000 rpm at 5°C in a  Sorvall SS-34 rotor. The resulting gradients 
were held on ice for up to 5 h before use. 
Isolation of Human Monocytes.  "Buffy coat" from  1 U  of fresh human blood was prepared by 
the Greater New York Blood Center as described (28).  We obtained the preparation 2  3 h after 
the blood was drawn. The buffy coat (average volume of 40 ml) was diluted twofold with saline 
containing  1 mM  EDTA, pH  7.4,  and  mononuclear  cells were separated  from other formed 
elements  of the  blood  by  centrifugation  on  step  gradients  of Ficoll-Paque  as  described  by 
Boyum  (29).  The  mononuclear  cells  were  washed  three  times  in  cold  RPMI  1640  (Gibco 
Laboratories,  Grand  Island,  NY)  to remove platelets, and  the cells were suspended  to 2-5  × 
107/ml  in  RPMI  made  10%  in  NHS.  5  ml  of this  suspension  was  layered  on  each  Percoll 
gradient  and the tubes were promptly centrifuged at  1,500 g  for 25 min at 5°C in a  swinging 
bucket  rotor.  The  resulting  bands  were  easily  detected  by  light  scattering.  The  midpoint 
between the two major bands  was  marked  and  the entire gradient  was  fractionated  into an 
upper half (band I) and a lower half (band II). Cells from bands I and II from several gradients 
were pooled and promptly washed twice in cold RPMI  1640. 
Culture of Human Monocytes.  Purified  monocytes were cultured  in screw cap Teflon  (PFA) 
jars  (Savillex,  Minnetonka,  MN)  or  in  Teflon  (FEP)  beakers  (Nalge  Co.,  Rochester,  NY) 
covered with foil. In experiments where continuous observation was required, cells were cultured 
in a  Teflon film apparatus  described  by van  der  Meer et  al.  (12).  Purified  monocytes were 
added  to  Teflon  vessels  at  106/ml  in  RPMI  1640  made  12.5%  in  NHS,  and  cultures  were 
incubated at 37°C in a  5% CO2 atmosphere. 
Viability and Efficiency of Plating.  The  plating  efficiency of phagocytes  on  a  tissue-culture 
plastic surface treated with HSA was measured by using a hemocytometer to count the number 
of cells in culture fluids before and after attachment.  The data obtained by this method were 
confirmed  by  cell  counts  made  on  low-magnification  photographs  taken  before  and  after 
washing away nonadherent cells. Cell viability was assessed by trypan blue (Gibco Laboratories) 
exclusion. 
Results 
Purification  and  Culture  of Human  Monocytes.  Table  I  describes  a  purification  of 
human  monocytes that  is representative of >40  separate  preparations.  Mononuclear 
cells  were  first  isolated  by  centrifugation  on  step  gradients  of Ficoll-Paque.  In  the SAMUEL D.  WRIGHT AND SAMUEL C.  SILVERSTEIN  1153 
TABLE  I 
Purification of Human Monocytes  from Buffy Coat 
Total leuko-  Peroxi-  Morphologi-  Total mon-  Yield of 
Fraction  cytes ×  106*  NSE+  dase  +  cally mono-  ocytes  mono- 
cytes:~  ×  106§  cytes 
%  %  %  % 
Buffy coat  1,920  16  69  13  278  100 
Ficoll-Paque  730  35  42  33  267  96 
interface 
Percoll band I  230  88  94  94  212  76 
Percoll band II  509  2  0.5  3  9.2  3 
* To determine the number of leukocytes in buffy coat, a sample was briefly exposed to distilled water to 
lyse erythrocytes and leukocytes were counted in a hemocytometer. 
:~ Based on nuclear morphology after Diff-Quik staining. 
§ The number for monocyte content  is the average obtained using three separate criteria for identifying 
monocytes: nuclear morphology, peroxidase staining, and NSE staining.  In calculating the number of 
monoeytes in the starting buffy coat material, the peroxidase data were not included because most of the 
peroxidase-positive cells were polymorphonuelear  leukocytes. 
TABLE II 
Culture of Human Monocytes in Teflon Beakers* 
Days in  Cells/  Viabil-  Plating el-  Peroxi-  NSE+  Elg43  EC3b  EC3b'  Protein/10  s  Binucleate  Units ~-glucuron- 
culture  beaker  ity  ficiency  dase+  binding  binding  binding  cells*  cells  idase/l0  n cells 
%  %  %  %  %  %  %  /.~  % 
0  3.8  100  90  88  87  92  87  89  41.5  0  4,5 
1  3.3  89  50  85  87  95  88  87  41.6  0  5,8 
3  3.8  95  80  45  96  96  100  100  90.7  0  12.5 
5  3.3  99  90  0  97  99  I00  100  135  0.9  53.6 
7  2.7  98  90  0  97  100  lfl0  100  201  1.8  107 
9  2.6  90  75  0  96  100  100  100  230  8.5  t25 
* 4 X  10  n monocytes were added to 50-ml Teflon beakers in a total volume of 5.0 ml RPMI  1640 made 12.5%  in fresh NHS, At the indicated times, cells 
were harvested for assay. 
:~ Values for protein content are averaged from three separate experiments. 
second step, monocytes were separated from lymphocytes by Percoll gradient centrif- 
ugation.  Band  I  (88-95%  monocytes)  was  centered  on  fractions  of specific gravity 
1.065  and was separated from the lymphocyte band  (band II, specific gravity  1.071) 
by  nearly  a  centimeter,  which  allowed  easy  fractionation.  Importantly,  band  I 
contained  70-85%  of all the monocytes  in  the starting material.  Only  2-8%  of the 
monocytes could be recovered in the remainder of the gradient  (band II). Thus,  the 
purified  monocyte  fraction  routinely contains  >95%  of the  recoverable monocytes. 
The  cells  in  band  I  were  identified  as  monocytes  by  a  number  of  morphologic, 
histochemical  (nonspecific esterase  [NSE]  and  peroxidase staining),  and  functional 
(Fc, C3b, and C3b' receptors) criteria (Tables I and II). 
The  purified  monocytes  (band  I)  were  cultured  in  Teflon  vessels to  which  they 
adhere lightly or not  at all. Cell number  remains relatively constant  during culture 
(Table  II),  which  indicates  that  the  monocytes  do  not  die  or  divide.  Rather,  as 
described previously (28, 30, 3 l), the cells differentiate into macrophages. They lose 
peroxidase  granules  and  retain  nonspecific  esterase  activity,  but  increase  in  size, 
protein content, and lysosomal enzyme content. Cell fusion begins after 5 d  in culture, 
resulting in a  variable number of binucleate or multinucleate cells (Table II). 
Receptor Activity of Cultured Monocytes.  Except after the first 24 h  in culture, mono- 1154  ACTIVATION OF  C3  RECEPTORS  ON  CULTURED  HUMAN  MONOCYTES 
cytes showed a  very high plating efficiency (Table II). Therefore, the adherent  cell 
population derived from a Teflon culture represents the whole population and not a 
selected subpopulation. When adherent cells from Teflon culture were tested for their 
ability to bind IgG-, C3b-, or C3b'-coated erythrocytes, nearly all phagocytes (~90%) 
showed strong rosetting with all three types of particles.  During differentiation,  the 
fraction of phagocytes capable of binding the ligand-coated E remained high, whereas 
the number of E  bound  per phagocyte increased,  which  resulted  in a  progressively 
rising attachment index (Fig. 2). 
The capacity of monocytes to phagocytose EIgG also increased during differentia- 
tion,  but  the  ability  of cultured  monocytes  to  ingest  EC3b  or  EC3b'  remained 
remarkably low  (Fig.  2):  we  confirm  the  results  of Newman  et  al.  (6)  that,  upon 
extended culture, a small amount of complement-mediated phagocytosis can be seen, 
that C3b' is a  more effective ligand  than C3b  (Fig.  2), and that the amount of C3- 
mediated  phagocytosis seen  varies from preparation  to preparation.  The  failure of 
monocytes to ingest C3-coated E is not caused by an inhibitory effect of C3b or C3b' 
on  the  monocytes  phagocytic  capacity  since  rosetted  EC3b  or  EC3b'  are  readily 
ingested upon the addition of anti-E IgG (data not shown). 
Modulation of Complement Receptor Activity in Cultured Monocytes.  Ligand-bearing sub- 
strates were constructed using ligand-coated E. C3-coated and control E were attached 
as a  monolayer to PLL-coated plastic, the E  were hypotonically lysed, and cultured 
monocytes were allowed to attach to and spread on the resulting G  monolayer. The 
receptor activity on the monocyte's nonadherent surface was then determined with a 
rosette assay. Table III shows that monocytes on IgM-coated G  monolayers retained 
full ability to bind EIgG, EC3b, and EC3b'. When plated on IgG-bearing G, the Fc 
receptors  modulated,  i.e.,  EIgG  no  longer  were  bound  to  the  cells'  nonadherent 
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FiG.  2.  Development  of complement  receptor  activity  and  Fc  receptor  activity  on  monocytes 
cultured  in Teflon  vessels. After various periods in culture,  phagocytes were harvested and  both 
attachment  index  (AI)  and  phagocytic  index  (PI)  were measured  with  EC3b,  EC3b',  or  EIgG. 
Phagocytes were allowed to attach to plastic culture surfaces either in the absence (O) or presence 
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surfaces,  whereas  their  C3b  and  C3b'  receptor activity  remained  unaltered.  In  a 
similar fashion, when monocytes were plated on C3b-bearing G, only the C3b receptor 
activity modulated,  and  when  spread  on  EC3b'-coated G, only the  C3b'  receptor 
activity modulated (Table III). 
In a second type of experiment, C3 was attached directly to the plastic substrate by 
constructing complement enzymes on antibody-coated surfaces  (Table IV).  C3b or 
C3b' receptor modulation occurred only when the corresponding ligand was deposited 
on the surface. In contrast to the C3b receptors, the C3b' receptors seldom disappeared 
completely when the cells were plated on a C3b' substrate: usually a large percentage 
of macrophages  had  a  number of erythrocytes still  adherent  (Tables III  and  IV). 
These results  agree qualitatively with those of Arend  and  Massoni  (32), who used 
TABLE  III 
Modulation of Receptor Activity on Monocytes Spread on Monolayers of 
Ligand-bearing Erythrocyte G* 
Surface 
Test particle 
EIgG  EC3b  EC3b' 
GIgM  100  100  100 
GIgG  0  130  104 
GC3b  99  17  102 
GC3b'  105  103  43 
* E  bearing the indicated ligands were attached to PLL-plastic surfaces and 
lysed as described in  Materials  and Methods. Freshly isolated or cultured 
monocytes were allowed to adhere to these surfaces for 45 min at 37°C, then 
the receptor  activity on the apical  surface of the phagocytes was assessed 
with a rosette assay. The results are averaged for seven separate experiments 
from which the AI obtained on control (GIgM) surfaces was first normalized 
to 100. Parallel experiments showed that the attachment index obtained for 
phagocytes on GIgM surfaces was essentially identical to that obtained with 
phagocytes spread on tissue culture plastic and that the plating efficiency of 
monocytes on G surfaces was similar to that obtained with plastic surfaces. 
TABLE IV 
Modulation of Receptor Activity on Mononuclear Phagocytes Spread on 
Ligand-bearing Culture Surfaces* 
Surface 
Test particle 
EC3b  EC3b'  EIgG 
HSA  750 (87%)  1450 (100%)  960 (87%) 
IgG  630 (69%)  1330 (100%)  55 (19%) 
IgGC1  520 (75%)  1250 (100%)  37 (15%) 
IgGCI4  620 (73%)  1450 (100%)  53 (14%) 
IgGC142  610 (70%)  1400 (100%)  26 (13%) 
IgGC1423b  77 (20%)  1400 (100%)  30 (8%) 
IgGC1423b'  599 (82%)  650 (81%)  72 (21%) 
* Tissue culture surfaces were coated with DNP as described in Materials and 
Methods. They were then incubated with HSA or anti-DNP-IgG, followed 
by the indicated complement components. Day-8 cultured monocytes were 
allowed to adhere to the indicated surfaces for 45  min at  37°G.  Receptor 
activity on the apical surfaces of the cell was assessed with a  rosette assay 
using the indicated test particles. Results are expressed as attachment indices, 
and the percent of phagocytes binding at least one E is given in parentheses. 1156  ACTIVATION OF C3  RECEPTORS  ON  CULTURED  HUMAN  MONOCYTES 
mouse complement as a  ligand. 
Effect of PMA on C3b and C3b' Receptor Function.  Cultured human monocytes can be 
stimulated to take up complement-coated erythrocytes by treatment  with the tumor 
promoter, phorbol  myristate acetate  (PMA).  A  dramatic increase in the phagocytic 
index for both EC3b and EC3b' was seen after treatment of phagocytes with as little 
as 3  ng/ml  PMA  (Table V).  The ability of PMA  to stimulate C3-mediated phago- 
cytosis appears to be related to the ability of this drug to promote tumorigenesis, as 
the nontumorigenic PMA-analogues PTA, 4-~-PDD, and 4-c~-PHR were inactive in 
stimulating complement-mediated phagocytosis. The active tumor-promoting deriv- 
ative PDD,  however, did stimulate phagocytosis (Table V). 
The effects of the active phorbol esters (PMA and PDD) on the C3 receptors do not 
reflect  a  general  enhancement  of cellular phagocytic  capacities.  PMA-treated  and 
control  monocytes  ingested  similar  numbers  of  EIgG.  Moreover,  PMA  did  not 
promote ingestion of E  attached to cultured monocytes with concanavalin A  (Table 
V). Thus, the stimulatory effect of PMA on receptor function appears specific for the 
C3 receptors. 
To confirm that  the phagocytosis of EC3b  and EC3b' by PMA-stimulated mono- 
cytes was  not  caused  by  trace contamination  of anti-EIgG,  all  Fc receptor activity 
was  depleted  from  the  nonadherent  surface  of the  phagocytes by  plating them  on 
immune complex-coated surfaces. EC3b and EC3b' were still phagocytosed by PMA- 
stimulated, mature monocytes depleted of Fc receptors (Table VI). 
The ability of monocytes to respond to PMA is developmentally regulated. Freshly 
explanted monocytes did not phagocytose EC3b  or EC3b' even after PMA  stimula- 
tion, but with time in culture they gained the capacity to ingest C3-bearing erythro- 
cytes in response to PMA treatment  (Fig. 2). 
To further characterize the C3b and C3b' receptors, we studied the effect of ligand 
density on  binding and phagocytosis of EC3b  and  EC3b'.  E  were prepared bearing 
TABLE  V 
The Effect of PMA and Its Analogues on the Phagocytosis of Ligand-bearing 
E by Cultured Monocytes* 
Test particle  Present during 
plating  EC3b  EC3b'  EIgG  ECon A:~ 
0  14 (8%)  76 (26%)  1,414  (100%)  0 (0%) 
PMA, 3 ng/ml  146 (11%)  151  (21%)  1,075  (100%)  4 (2%) 
PMA, 10 ng/ml  464 (28%)  388 (38%)  1,275  (100%)  27 (12%) 
PMA, 30 ng/ml  454 (56%)  511  (65%)  1,070  (100%)  28 (13%) 
PMA, 100 ng/ml  525 (58%)  785 (75%)  1,367  (100%)  55 (29%) 
PDD  332 (55%)  680 (96%)  580 (85%)  35 (16%) 
4-o~-PDD  7 (6%)  65 (21%)  1,195  (100%)  0 (0%) 
PTA  19 (12%)  53 (17%)  1,005  (100%)  0 (0%) 
4-a-PHR  31 (14%)  57 (21%)  1,440  (89%)  0 (0%) 
* Day 6 cultured monocytes were incubated for 45 rain with various concen- 
trations of PMA or with PDD, 4-a-PDD, PTA, or 4-a-PHR at 30 ng/ml. 
Cells were then  washed and the phagocytic  index  was assessed with  the 
indicated ligand-bearing E. The percent of phagocytes ingesting at least one 
E is given in parentheses. Under all conditions shown and with all ligand- 
bearing E used, AI exceeded 1,000. 
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TABLE VI 
Fc Receptor Function Is Not Required  for PMA-stimulated  Phago~tosis of 
EC3b and EC3b'* 
Surface 
Particle  DNP  DNP-anti-DNP IgG  offered 
-  +PMA  -  +PMA 
EC3b  8 (4%)  815 (79%)  7 (4%)  330 (58%) 
EC3b'  190 (36°70)  807 (87%)  22 (14%)  482 (74%) 
EIgG  860 (80%)  1390 (94%)  33 (19%)  40 (27%) 
* After 7 d in culture, monocytes were plated on DNP-anti-DNP IgG-coated 
surfaces or on control DNP-coated surfaces in the presence or absence of 30 
ng/ml PMA. The cells were then washed  and the PI was  measured with 
EC3b, EC3b', or EIgG. The percent of cells ingesting at least one E is given 
in parentheses. 
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different numbers  of C3b, C3b', or IgG, and both attachment  and phagocytic indices 
were  determined  with  5-d-cultured  monocytes  in  the  presence  or  absence  of PMA 
pretreatment  (Fig.  3).  Approximately  15,000  molecules  of  C3b/E  produced  half- 
maximal  rosetting,  and  even  fewer  C3b'  (5,000/E)  yielded  half-maximal  rosetting. 
Approximately  10,000  IgG/E  were needed for half-maximal rosetting. 
In the absence of PMA,  a  small amount  of complement-mediated  phagocytosis was 
seen in cells after a  number  of days in culture (Fig. 2). Under  these conditions, at least 
30,000  C3b'/E  were required  to produce  detectable  ingestion. Treatment  of cultured 1 158  ACTIVATION OF C3  RECEPTORS ON CULTURED HUMAN MONOCYTES 
monocytes with PMA causes a  qualitative  change in the physiology of the C3b and 
C3b' receptors: these receptors can now mediate phagocytosis. The density of ligands 
required for half-maximal phagocytosis by PMA-treated phagocytes is similar for IgG 
and C3b' (~ 10,000/E;  Fig.  3), which suggests that  in appropriately stimulated  cells, 
the receptors for these two ligands are similar in their ability to generate a phagocytic 
signal.  PMA-stimulated cells do ingest C3b-coated E, but a  10-fold-higher density of 
C3b is required  to match the phagocytosis mediated by 10,000 molecules/E of either 
C3b' or IgG. 
PMA has been shown to cause release of proteases from macrophages (33), and the 
C3b  receptor  has  been  shown  to facilitate  the  cleavage of cell-bound  C3b  to C3b' 
(34). It was possible, therefore, that enzyme(s) secreted by PMA-stimulated monocytes 
cleaved  E-bound  C3b  to  C3b'  and  that  the  resultant  C3b'  mediated  phagocytosis 
through interaction  with  the C3b' receptor.  To test  this  possibility,  monocytes were 
plated on C3b'-coated surfaces to modulate their C3b' receptors. The monocytes were 
treated  with  PMA  to  stimulate  the  activity  of their  C3  receptors,  and  were  then 
incubated with EC3b. Despite a significant reduction in C3b' receptor function, these 
monocytes ingested  as  many  EC3b  as  monocytes plated  on  control  (IgM)  surfaces 
(Table  VII).  Conversely,  monocytes plated  on C3b-coated substrates  phagocytosed 
virtually  no  C3b-coated  E,  even  though  their  C3b'  receptors  remained  functional 
(Table  VII).  In  other  experiments,  K76COOH,  a  potent  inhibitor  of I  (35),  at  a 
concentration of 1 mg/ml had no inhibitory effect on the uptake of EC3b by PMA- 
stimulated monocytes (data not shown). Finally, we have found that both Ca and Mg 
ions  (0.15  and 0.25  raM, respectively)  are required  to support  optimal  binding and 
phagocytosis of EC3b' by mononuclear phagocytes, but are not required  for optimal 
binding and phagocytosis of EC3b  (Table VIII). 
These  results  indicate  that  after  stimulation  by  PMA,  the  C3b  and  the  C3b' 
receptors  function  independently  of one  another  in  promoting  the  ingestion  of E 
coated with the corresponding ligands.  Although they do not exclude the possibility 
that  monocyte-derived  proteases  cleave  some  of the  ligated  C3b  molecules,  they 
provide direct evidence that EC3b are ingested via the monocyte's C3b receptors. 
The stimulatory effect of PMA on C3 receptor-mediated  phagocytosis is relatively 
stable and occurs rapidly. The effect was observed when the PMA was added for 45 
min  and  washed  away before  addition  of the  ligand-coated  E  (Table  V),  or when 
TABLE  VII 
PMA-stimulated Phagocytosis by Cultured Monocytes Spread on Monolayers of 
L2gand-bearing E~ythrocyte G* 
Surface 
Test particle 
EIgG  EC3b  EC3b' 
GIgM  660 (80%)  292 (70%)  391 (76%) 
GC3b  945 (71%)  13 (6%)  244 (60%) 
GC3b'  775 (84%)  300 (52%)  160 (53%) 
GIgG  5 (2%)  331 (75%)  450 (73%) 
* E bearing the indicated ligands were attached  to PLL-plastic surfaces and 
lysed as described in  Materials and Methods. Day-6 cultured  monocytes 
were allowed to adhere for 45 min at 37°C in the presence of 75 ng/ml PMA. 
The cells were then washed and the PI was measured with EC3b, EC3b', or 
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TABLE  VIII 
Effect of Divalent Cations on the Binding and Phagocytosis of 
Ligand-coated E* 
Test particle 
Divalent cations  EC3b  EC3b'  EIgG  present 
AI  PI  AI  PI  AI  PI 
0.5 mM Ca  ++ 
and 0.5 mM 
Mg  +*  2,292  216  2,213  260  2,210  528 
0.5 mM Ca**  2,222  181  367  101  2,028  374 
0.5 mM Mg  ÷+  2,333  159  47 l  98  2,264  375 
None  2,090  130  177  11  2,400  336 
7°d cultured monocytes were incubated for 45 min in PBSG containing 30 
ng/ml PMA. The cells were then thoroughly washed in phosphate buffer 
free  of divalent  cations  and  the  AI  and  PI  were  determined  using  the 
indicated test particles suspended in buffer containing the indicated cations. 
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TABLE  IX 
Effect of Drugs on PMA-stimulated Phagocytosis of Ligand-bearing E* 
Present during  Present during  Test particle 
plating  phagocytosis  EC3b  EC3b'  EIgG 
--  --  22 (11%)  84 (27%)  995 (90%) 
PMA  --  414 (47%)  654 (86%)  1060 (89%) 
--  PMA  415 (65%)  488 (70%)  1070 050) 
PMA  Colchicine  61 (21%)  142 (27%)  570 (88%) 
PMA  Podophyllotoxin  87 (25%)  134 (22%)  590 (85%) 
Cycloheximide  Cycloheximide  430 (43%)  616 (88%)  891 (84%) 
and PMA 
After 6 d in culture, monocytes were allowed to adhere to plastic surfaces for 
45 rain at 37°C in the presence or absence of 30 ng/ml PMA as indicated. 
When used, 10 #g/ml cycloheximide was incubated with the cells for 10 rain 
before the addition of PMA. Cells were  then washed and incubated with 
ligand-coated E  in the presence or absence of colchicine, podophyllotoxin 
(both at 10  -s M), or PMA (30 ng/ml). Results are expressed as PI, and the 
percent of cells ingesting at least one E is given in parentheses. 
added  at  the same  time as  the E  (Table  IX).  When  PMA  was  added  to  phagocyte- 
EC3b  or EC3b'  rosettes,  interiorization of bound  E  occurred  rapidly  (within  10 min, 
data  not shown). 
Griffin and Griffin (9) and Griffin and Mullinax  (10) have shown that T  cell factor- 
mediated  activation  of complement  receptors  in  mouse  macrophages  is not  affected 
by cycloheximide  hut  is blocked by  treatment  of the macrophages  with  agents  that 
depolymerize  microtubules.  We  have found  similar effects with the PMA-stimulated 
phagocytosis of EC3b  and  EC3b':  when  added  to washed,  PMA-stimulated  cells, the 
microtubule  depolymerizing  agents colchicine and podophyllotoxin  reversed the effect 
of PMA;  complement  receptor-mediated  phagocytosis was no longer seen (Table IX). 
Cycloheximide,  on  the  other  hand,  caused  no  alteration  in  the  PMA-stimulated 
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Discussion 
Our results confirm that monocytes bear receptors for C3b  and  C3b'  but  not  for 
C3d  (3-6),  and  that  the  C3b  and  C3b'  receptors  function  independently  of one 
another in a  single cell (Tables III, IV, VII, and VIII) (3).  The presence of separate 
receptors for two closely related ligands on a  single cell type may be puzzling, but it 
is  not  without  precedent.  Mouse  (36)  and  human  (37)  macrophages  bear  several 
distinct  receptors for the Fc regions of IgG. It is possible that multiple C3 receptors 
are required because different forms of C3 may predominate on different particles in 
vivo. Per molecule of particle-bound ligand, the C3b' receptor is 3 times more efficient 
in promoting attachment and 10 times more efficient in promoting ingestion than the 
C3b receptor  (Fig.  3).  Further,  C3b' is relatively stable in serum, whereas C3b can 
often be rapidly degraded  (2).  Thus, in vivo, the outcome of an interaction between 
a  mononuclear phagocyte and  a  C3-coated  particle  is likely to be governed by the 
cell's C3b' rather than its C3b receptors. 
Activation of C3 and C3b' Receptors by Phorbol Esters.  C3  is widely recognized as an 
essential opsonic ligand (38). Thus, it is puzzling that the C3 receptors on unstimulated 
human  (6),  mouse (7),  and guinea pig (39)  mononuclear phagocytes do not mediate 
the ingestion of E  coated with the corresponding ligand.  Mouse and guinea pig C3 
receptors can be activated by lymphokines and  inflammatory stimuli  (8,  39,  40).  It 
seems likely, therefore, that PMA is mimicking a similar regulatory substance that is 
the physiological activator of these receptors in man. 
Several lines of evidence indicate  that  cells bear specific membrane receptors for 
phorbol esters (41,  42). Thus, the failure of PMA to activate C3 receptors on freshly 
explanted  monocytes could  reflect  a  lack of receptors  for PMA  on  these  cells.  We 
think this unlikely because PMA stimulates adherence, spreading, and H202 secretion 
by freshly explanted  monocytes (28).  Moreover, compounds such  as interferon  that 
inhibit the maturation of monocytes also block the acquisition of PMA-stimulatable 
C3 receptor activity (S.  D. Wright and S.  C. Silverstein, unpublished  observations). 
Once human monocytes reach an appropriate stage of differentiation, PMA induces 
activation of C3 receptors within a few minutes and without a requirement for protein 
synthesis (Table IX). For these reasons, we think that qualitative changes that occur 
as monocytes mature to macrophages govern the responsiveness of C3  receptors  to 
PMA, and that PMA inducibility of C3 receptor function  may be a  marker for this 
transition. 
We  do  not  understand  the  mechanism(s)  by  which  PMA  makes  complement 
receptors capable of generating a phagocytic signal. Possible mechanisms include:  (a) 
insertion of competent receptors into the plasma membrane from an internal  pool; 
(b) covalent modification  (e.g., phosphorylation, methylation, etc.) of existing recep- 
tors; and (c) insertion of coupling factors that might interact with ligated C3 receptors 
to generate a phagocytic signal. With respect to this last possibility, it should be noted 
that Fc receptors are constitutively competent to mediate phagocytosis. Thus, if other 
factors  are  required  to  promote  complement  receptor-mediated  phagocytosis,  the 
putative  factors  that  interact  with  C3  receptors  must  be  distinct  from  those  that 
interact with Fc receptors. 
Comparison of Murine and Human C3 Receptors.  This study confirms an  interesting 
difference  in  the  behavior  of  C3  receptors  of  mouse  and  human  mononuclear 
phagocytes.  Complement  receptors of unstimulated  mouse peritoneal  macrophages SAMUEL D. WRIGHT AND SAMUEL C.  SILVERSTEIN  1161 
appear to be immobile because they are not modulated when those cells are plated on 
C3-bearing surfaces (24). Those macrophages do not ingest C3-coated E. Complement 
receptors of lymphokine-treated (10) or thioglycollate broth-elicited macrophages (24) 
appear  to  be  mobile  because  they  are  modulated  by  C3-bearing  surfaces.  These 
maerophages ingest C3-coated E via their complement receptors. The above findings 
led Michl et al. (24)  to suggest that C3 receptor mobility is required for C3 receptor- 
mediated uptake of C3-coated particles.  The present  study and  that of Arend  and 
Massoni  (32)  show  that  C3  receptors on human  monocytes are mobile,  at  least  as 
measured by their capacity to modulate in response to C3-coated surfaces. Neverthe- 
less, in the absence of stimulation by PMA, these receptors do not mediate phagocy- 
tosis  of C3-coated  E.  Thus,  receptor  mobility  may  be  necessary  for  C3  receptor- 
mediated phagocytosis to occur, but the presence of mobile receptors is not sufficient. 
Evidently, several steps are required to enable C3 receptors to generate a  phagocytic 
signal.  We suggest  that  unstimulated  mouse  and  human  mononuclear  phagocytes 
illustrate different intermediate stages in this process. 
Summary 
Monocytes  were  isolated  in  high  yield  (~80%)  and  purity  (>90%)  by  Percoll 
gradient  centrifugation  and  incubated  in  Teflon culture  vessels. Using this culture 
method, we routinely recovered 80% of the cells originally placed into culture. Studies 
of the C3b and C3b' receptors of these monocytes showed that the function of both 
receptors could be dramatically altered by treating the cells with tumor-promoting 
phorbol esters. Both C3b and C3b' receptors of human monocytes efficiently mediate 
attachment oferythrocytes coated with the corresponding ligands, but do not promote 
their ingestion.  However, monocytes treated with phorbol myristate acetate (PMA) 
or phorbol didecanoate ingest C3b- and C3b'-coated erythrocytes. Phorbol esters that 
are inactive as tumor promoters do not stimulate C3 receptor-mediated phagocytosis. 
The  ability  of  monocytes  to  respond  to  PMA  by  activation  of  C3  receptors  is 
developmentally regulated. Freshly isolated monocytes do not take up C3b- or C3b'- 
coated erythrocytes in  response to PMA,  but  after 3  d  of culture  they show strong 
PMA-stimulated uptake. The stimulatory effect of PMA on monocyte C3b and C3b' 
receptor function occurs within minutes, is stable for hours, is cycloheximide insensi- 
tive, and  can be inhibited  with  colchicine.  Several  lines  of evidence indicates  that 
phagocytosis  of C3b  or  C3b'-coated  erythrocytes  is  specifically  mediated  by  the 
monocytes' C3b and C3b' receptors. First, erythrocytes attached to monocytes with 
concanavalin A are not ingested when the monocytes are treated with PMA. Second, 
monocytes plated on IgG-bearing substrates lose Fc receptor activity on their nonad- 
herent  surfaces but  retain  the  capacity to  ingest  C3b- or C3b'-coated erythrocytes 
after PMA treatment. Third, PMA-treated monocytes plated on C3b-coated surfaces 
lose C3b  receptor activity on their nonadherent  surfaces but  retain  the capacity to 
ingest C3b'-coated erythrocytes. Conversely, PMA-treated monocytes plated on C3b'- 
coated surfaces show reduced C3b' receptors activity on their nonadherent  surfaces 
but retain the capacity to ingest C3b-coated erythrocytes. 
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